The Cell And Gene Therapy CDMO Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Phase (Pre-clinical, Clinical, By Product (Gene Therapy (Ex-vivo, In-vivo, Gene-Modified Cell Therapy, CAR T-cell therapies, CAR-NK cell therapy, TCR-T cell therapy, Others), Cell Therapy), By Indication (Oncology, Infectious Diseases, Neurological disorders, Rare Diseases, Others).
In 2024, the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market stands at the forefront of innovation and progress within the biopharmaceutical industry. With an escalating demand for personalized and groundbreaking therapeutic approaches, CDMOs play a pivotal role in facilitating the development, manufacturing, and commercialization of cell and gene therapies. The market is characterized by a surge in strategic partnerships, technological advancements, and a robust regulatory landscape, all contributing to the seamless integration of these transformative therapies into mainstream healthcare. As the industry continues to witness a surge in research and development activities, the Cell and Gene Therapy CDMO Market is poised for remarkable growth, ensuring the efficient and scalable production of cutting-edge therapies that hold immense potential for addressing previously unmet medical needs.
The most prominent trend in the Cell and Gene Therapy CDMO (Contract Development and Manufacturing Organization) market is the significant surge in cell and gene therapy research and development activities. As the field of regenerative medicine advances, there is a growing focus on personalized and targeted therapies, leading to an increased demand for CDMOs to provide specialized services for manufacturing these intricate cell and gene therapy products. The trend reflects the industry's dynamic response to the evolving landscape of advanced therapies.
A key driver in the Cell and Gene Therapy CDMO market is the accelerated pace of regulatory approvals and commercialization of cell and gene therapy products. With regulatory agencies increasingly recognizing the potential of these therapies and streamlining approval processes, there is a growing need for CDMOs to support manufacturers in efficiently navigating the complex regulatory landscape. This driver reflects the market's responsiveness to the urgency of bringing innovative therapies to patients and the critical role CDMOs play in ensuring compliance and quality in manufacturing.
An opportunity within the Cell and Gene Therapy CDMO market lies in the global expansion of CDMO services. As the demand for cell and gene therapies grows worldwide, there is an opportunity for CDMOs to expand their geographical presence and offer their expertise on a global scale. This involves establishing strategic partnerships, collaborations, and facilities in emerging markets, facilitating broader accessibility to CDMO services and supporting the globalization of cell and gene therapy advancements.
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
Cell And Gene Therapy CDMO Market
*List not exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cell And Gene Therapy CDMO Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cell And Gene Therapy CDMO Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Cell And Gene Therapy CDMO Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Cell And Gene Therapy CDMO Market Size Outlook, $ Million, 2021 to 2030
3.2 Cell And Gene Therapy CDMO Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cell And Gene Therapy CDMO Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cell And Gene Therapy CDMO Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cell And Gene Therapy CDMO Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Cell And Gene Therapy CDMO Market Industry
4.2 Key Market Trends in Cell And Gene Therapy CDMO Market Industry
4.3 Potential Opportunities in Cell And Gene Therapy CDMO Market Industry
4.4 Key Challenges in Cell And Gene Therapy CDMO Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Cell And Gene Therapy CDMO Market Share by Company
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Cell And Gene Therapy CDMO Market Outlook By Segments
7.1 Cell And Gene Therapy CDMO Market Outlook by Segments
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
8 North America Cell And Gene Therapy CDMO Market Analysis And Outlook To 2030
8.1 Introduction to North America Cell And Gene Therapy CDMO Markets in 2024
8.2 North America Cell And Gene Therapy CDMO Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cell And Gene Therapy CDMO Market size Outlook by Segments, 2021-2030
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
9 Europe Cell And Gene Therapy CDMO Market Analysis And Outlook To 2030
9.1 Introduction to Europe Cell And Gene Therapy CDMO Markets in 2024
9.2 Europe Cell And Gene Therapy CDMO Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cell And Gene Therapy CDMO Market Size Outlook By Segments, 2021-2030
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
10 Asia Pacific Cell And Gene Therapy CDMO Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Cell And Gene Therapy CDMO Markets in 2024
10.2 Asia Pacific Cell And Gene Therapy CDMO Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cell And Gene Therapy CDMO Market size Outlook by Segments, 2021-2030
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
11 South America Cell And Gene Therapy CDMO Market Analysis And Outlook To 2030
11.1 Introduction to South America Cell And Gene Therapy CDMO Markets in 2024
11.2 South America Cell And Gene Therapy CDMO Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cell And Gene Therapy CDMO Market size Outlook by Segments, 2021-2030
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
12 Middle East And Africa Cell And Gene Therapy CDMO Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Cell And Gene Therapy CDMO Markets in 2024
12.2 Middle East and Africa Cell And Gene Therapy CDMO Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cell And Gene Therapy CDMO Market size Outlook by Segments, 2021-2030
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Lonza
CatalentInc
Cytiva
Samsung Biologics
Thermo Fisher Scientific Inc
Novartis AG
WuXi AppTec
AGC Biologics
OmniaBio
Rentschler Biopharma SE
Charles River Laboratories
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Phase
Pre-clinical
Clinical
By Product
Gene Therapy
Ex-vivo
In-vivo
Gene-Modified Cell Therapy
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
Cell Therapy
By Indication
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
Cell And Gene Therapy CDMO Market
The global Cell And Gene Therapy CDMO Market is one of the lucrative growth markets, poised to register a 24.5% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Lonza, CatalentInc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc, Novartis AG, WuXi AppTec, AGC Biologics, OmniaBio, Rentschler Biopharma SE, Charles River Laboratories
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume